Corcept Therapeutics Inc CORT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CORT is a good fit for your portfolio.
News
-
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
-
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
-
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
-
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
-
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
-
Corcept Completes Enrollment in Phase 4 CATALYST Trial
-
20 companies screened for quality in a cheap part of the stock market
-
20 companies screened for quality in a cheap -2-
Trading Information
- Previous Close Price
- $34.87
- Day Range
- $34.90–35.95
- 52-Week Range
- $20.84–35.95
- Bid/Ask
- $35.00 / $39.22
- Market Cap
- $3.71 Bil
- Volume/Avg
- 901,765 / 1.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- 43.95
- Price/Sales
- 7.50
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 3.92%
Company Profile
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 352
- Website
- https://www.corcept.com
Comparables
Valuation
|
Metric
|
CORT
|
NBIX
|
RIGL
|
|---|---|---|---|
Price/Earnings (Normalized) | 43.95 | 26.55 | — |
Price/Book Value | 6.76 | 6.19 | — |
Price/Sales | 7.50 | 7.60 | 1.56 |
Price/Cash Flow | 30.12 | 25.48 | — |
Price/Earnings
CORT
NBIX
RIGL
Financial Strength
|
Metric
|
CORT
|
NBIX
|
RIGL
|
|---|---|---|---|
Quick Ratio | 4.86 | 2.33 | 1.05 |
Current Ratio | 5.18 | 2.52 | 1.26 |
Interest Coverage | — | 98.90 | −1.95 |
Quick Ratio
CORT
NBIX
RIGL
Profitability
|
Metric
|
CORT
|
NBIX
|
RIGL
|
|---|---|---|---|
Return on Assets (Normalized) | 26.66% | 19.40% | −7.25% |
Return on Equity (Normalized) | 32.57% | 27.78% | — |
Return on Invested Capital (Normalized) | 29.30% | 23.85% | −11.44% |
Return on Assets
CORT
NBIX
RIGL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Rwxvhfxnm | Byhv | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Byhhzxzd | Hdbtch | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ggsfxsfjd | Nsjfj | $118.7 Bil | |||
| Moderna Inc
MRNA
| Whwsllhh | Srhx | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Lqtyykzb | Tkbxgjx | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Fxcvpdnf | Hqwl | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Pcpszphb | Ykp | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mtxpzgsb | Rhglj | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Kptvtzkl | Rlvjs | $15.0 Bil | |||
| Incyte Corp
INCY
| Gcwfmnyr | Hzyhq | $13.5 Bil |